These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 17683946)
21. NK cell triggering by the human costimulatory molecules CD80 and CD86. Wilson JL; Charo J; MartÃn-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG J Immunol; 1999 Oct; 163(8):4207-12. PubMed ID: 10510357 [TBL] [Abstract][Full Text] [Related]
22. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Kim KS; Denton MD; Chandraker A; Knoflach A; Milord R; Waaga AM; Turka LA; Russell ME; Peach R; Sayegh MH Am J Pathol; 2001 Mar; 158(3):977-86. PubMed ID: 11238045 [TBL] [Abstract][Full Text] [Related]
23. CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. Vasilevko V; Ghochikyan A; Holterman MJ; Agadjanyan MG DNA Cell Biol; 2002 Mar; 21(3):137-49. PubMed ID: 12015893 [TBL] [Abstract][Full Text] [Related]
24. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Chen L Nat Rev Immunol; 2004 May; 4(5):336-47. PubMed ID: 15122199 [No Abstract] [Full Text] [Related]
25. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell RA; Kerkvliet NI J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803 [TBL] [Abstract][Full Text] [Related]
26. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. Elloso MM; Scott P J Immunol; 1999 Jun; 162(11):6708-15. PubMed ID: 10352289 [TBL] [Abstract][Full Text] [Related]
27. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. Gajewski TF J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795 [TBL] [Abstract][Full Text] [Related]
28. The complex role of B7 molecules in tumor immunology. Seliger B; Marincola FM; Ferrone S; Abken H Trends Mol Med; 2008 Dec; 14(12):550-9. PubMed ID: 18986838 [TBL] [Abstract][Full Text] [Related]
29. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma. Chen YQ; Shi HZ Allergy; 2006 Jan; 61(1):15-26. PubMed ID: 16364152 [TBL] [Abstract][Full Text] [Related]
30. The B7 family and cancer therapy: costimulation and coinhibition. Zang X; Allison JP Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5271-9. PubMed ID: 17875755 [TBL] [Abstract][Full Text] [Related]
31. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Carreno BM; Collins M Annu Rev Immunol; 2002; 20():29-53. PubMed ID: 11861596 [TBL] [Abstract][Full Text] [Related]
32. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. Mitra RS; Judge TA; Nestle FO; Turka LA; Nickoloff BJ J Immunol; 1995 Mar; 154(6):2668-77. PubMed ID: 7533180 [TBL] [Abstract][Full Text] [Related]
33. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. Foster AE; Leen AM; Lee T; Okamura T; Lu A; Vera J; Atkinson R; Bollard CM; Dotti G; Rooney CM J Immunother; 2007; 30(5):506-16. PubMed ID: 17589291 [TBL] [Abstract][Full Text] [Related]
34. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231 [TBL] [Abstract][Full Text] [Related]
35. B7.2 (CD86) but not B7.1 (CD80) costimulation is required for the induction of low dose oral tolerance. Liu L; Kuchroo VK; Weiner HL J Immunol; 1999 Aug; 163(4):2284-90. PubMed ID: 10438973 [TBL] [Abstract][Full Text] [Related]
36. B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T-cell receptor. Chan AK; Goedegebuure PS; von Bernstorff W; Carritte AL; Chung M; Stewart RA; Montgomery L; Spanjaard RA; McKenzie AB; Eberlein TJ Surgery; 2000 Mar; 127(3):342-50. PubMed ID: 10715992 [TBL] [Abstract][Full Text] [Related]
38. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Habib-Agahi M; Phan TT; Searle PF Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894 [TBL] [Abstract][Full Text] [Related]
39. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322 [TBL] [Abstract][Full Text] [Related]
40. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Blanco B; Holliger P; Alvarez-Vallina L Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]